Fig. 5
From: Interleukin-17 promotes nitric oxide-dependent expression of PD-L1 in mesenchymal stem cells
IL-17-pretreated MSCs promote melanoma growth through enhancing PD-L1 expression on MSCs. a C57BL/6 MSCs were treated by PBS, or IFNγ and TNFα, or IFNγ, TNFα and IL-17 for 48 h. Pretreated MSCs (1 × 105) were then collected and injected subcutaneously together with B16F0 cells (2.5 × 105) on C57BL/6 mice (n = 9 each). On day 16, mice were euthanized and the resultant tumors were excised and weighed. b C57BL/6 MSCs were treated as in a with or without PD-L1 antibody (10 μg/ml). After 48 h, cells were collected for the detection of PD-L1 by flow cytometry. c C57BL/6 MSCs collected in b were then injected with B16 cells as in a (n = 5 each). On day 16, mice were euthanized and the resultant tumors were excised and weighed. d C57BL/6 MSCs (1 × 105) and B16 cells (2.5 × 105) were injected as in a. On day 1,4 and 7, PD-L1 antibodies (10 μg/g) were administrated intraperitoneously (n = 6 each). On day 16, mice were euthanized and the resultant tumors were excised and weighed. Statistical analysis was performed using the Student’s t-test. *p < 0.05, ns (not significant)